Compass Therapeutics(US:CMPX)2025-11-05 12:30Financial Performance - The net loss for Q3 2025 was $14.3 million, or $0.08 per share, compared to a net loss of $10.5 million, or $0.08 per share, for the same period in 2024[8] - The company reported a total operating loss of $15.8 million for Q3 2025, compared to $12.2 million for Q3 2024[17] - Total liabilities as of September 30, 2025, were $21.6 million, while total stockholders' equity was $209.6 million[20] Research and Development - Research and Development (R&D) expenses increased by 49% to $12.8 million in Q3 2025, up from $8.6 million in Q3 2024, primarily due to manufacturing and IND-enabling costs for CTX-10726[9] - CTX-10726 is on track for IND filing in Q4 2025, with initial Phase 1 clinical data expected in H2 2026[5] - The company plans to initiate a Phase 2 trial of CTX-471 in Q1 2026 for tumors expressing NCAM (CD56)[10] Cash Position - Cash and marketable securities as of September 30, 2025, were $220 million, up from $127 million as of December 31, 2024, providing a cash runway into 2028[12] - The financing round in August raised $138 million, supporting ongoing clinical development and expansion plans[3] Clinical Trials and Studies - The company expects to report overall survival (OS) and progression-free survival (PFS) data for tovecimig in late Q1 2026, based on a continuing trend of decreased mortality in the ongoing COMPANION-002 study[4] - Cohort expansions for CTX-8371 in patients with non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC) are expected to begin in Q4 2025[5]